4'-O-Methylbavachalcone

Name: 4'-O-Methylbavachalcone
Brand: MedChemExpress
SKU: HY-N1910
Rating: 5.0 (4 reviews)

Cat. No.: HY-N1910 Purity: 99.64%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

4'-O-Methylbavachalcone is an orally active prenylated flavonoid that inhibits the activity of SARS-CoV papain-like protease (PLpro), with an IC₅₀ of 10.1 μM and a K_i of 4.6 μM. 4'-O-Methylbavachalcone inhibits poly (ADP-ribose) polymerase-mediated cell death (parthanatos), reduces cerebral infarct volume, binds to the orthosteric site of SUCNR1, blocks the interaction between succinate and SUCNR1, inhibits SUCNR1 activity, blocks the nuclear translocation of NFATc4, suppresses the activation of the ERK1/2 signaling pathway, inhibits cardiomyocyte hypertrophy and restores the expression of α-actinin. 4'-O-Methylbavachalcone can be used in studies related to ischemic stroke, SARS-CoV and cardiomyocyte hypertrophy.

For research use only. We do not sell to patients.

4'-O-Methylbavachalcone Chemical Structure

CAS No. : 20784-60-5

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

4 Publications Citing Use of MCE 4'-O-Methylbavachalcone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 10.1 μM (PLpro)^[1]

In Vitro

4'-O-Methylbavachalcone (0-200 μM) acts as a mixed inhibitor of purified recombinant SARS-CoV PLpro with an IC₅₀ of 10.1 μM and a K_i value of 4.6 μM^[2].
4'-O-Methylbavachalcone (1.25-40 μM; 48 h) exhibits no cytotoxicity toward H9c2 cardiomyocytes at concentrations up to 40 μM after 48 h of treatment^[3].
4'-O-Methylbavachalcone (1.25-5 μM; 30 min pre-incubation prior to 1 mM sodium succinate stimulation for 60 min) concentration-dependently inhibits NFATc4 nuclear translocation in succinate-stimulated H9c2 cardiomyocytes, with 5 μM nearly restoring translocation to baseline levels, and reduces succinate-induced upregulation of the hypertrophic marker α-actinin in H9c2 cardiomyocytes^[3].
4'-O-Methylbavachalcone (1.25-5 μM; 30 min pre-incubation prior to 1 mM sodium succinate stimulation for 15 min) inhibits succinate-induced activation of ERK1/2 and JNK MAPK signaling in H9c2 cardiomyocytes, with maximum inhibition of ~15% for ERK1/2 and ~40% for JNK^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[3]

Cell Line:	Succinate-stimulated H9c2 cardiomyocytes
Concentration:	1.25 μM, 2.5 μM, 5 μM
Incubation Time:	30 min pre-incubation prior to 1 mM sodium succinate stimulation for 60 min
Result:	Inhibited NFATc4 nuclear translocation in a concentration-dependent manner, with 5 μM treatment reducing NFATc4 nuclear translocation nearly to prestimulation levels.

Real Time qPCR^[3]

Cell Line:	Succinate-stimulated H9c2 cardiomyocytes
Concentration:	1.25 μM, 2.5 μM, 5 μM
Incubation Time:	30 min pre-incubation prior to 1 mM sodium succinate stimulation for 6 h
Result:	Restored succinate-induced upregulation of α-actinin mRNA expression in H9c2 cells.

Western Blot Analysis^[3]

Cell Line:	Succinate-stimulated H9c2 cardiomyocytes
Concentration:	1.25 μM, 2.5 μM, 5 μM
Incubation Time:	30 min pre-incubation prior to 1 mM sodium succinate stimulation for 15 min
Result:	Significantly inhibited succinate-induced phosphorylation of ERK1/2 and JNK, with maximum inhibition of ~15% and ~40%, respectively.

In Vivo

4'-O-Methylbavachalcone (5-10 mg/kg; oral gavage; at 15 min post-occlusion, then daily until euthanasia at 48 h) dose-dependently reduces cerebral infarct volume (to 20.20% at 10 mg/kg), improves neurological function, and enhances neuron survival in MCAO/R rats by inhibiting parthanatos signaling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (SD) (male, 240 g ± 10 g, middle cerebral artery occlusion-reperfusion induced)^[1]
Dosage:	5 mg/kg; 10 mg/kg
Administration:	oral gavage; at 15 min post-occlusion, then daily until euthanasia at 48 h
Result:	Reduced cerebral infarct volume to 24.63%. Improved neurological deficit scores. Reduced cerebral infarct volume to 20.20%. Increased the ratio of NeuN-positive neurons in the ischemic penumbra from 47.23% to 79.76%. Significantly suppressed MCAO/R-induced increases in cytoplasmic PAR, cytoplasmic AIF, nuclear PAR, nuclear PARP-1, and nuclear AIF protein levels. Reduced nuclear translocation of AIF and PAR accumulation in the ischemic penumbra.

Molecular Weight

338.40

Formula

C₂₁H₂₂O₄

CAS No.

20784-60-5

Appearance

Solid

Color

Yellow to orange

SMILES

O=C(C1=CC(C/C=C(C)\C)=C(OC)C=C1O)/C=C/C2=CC=C(O)C=C2

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (147.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9551 mL	14.7754 mL	29.5508 mL
5 mM	0.5910 mL	2.9551 mL	5.9102 mL
10 mM	0.2955 mL	1.4775 mL	2.9551 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (6.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.64%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (245 KB) HNMR (234 KB) RP-HPLC (167 KB) MS (188 KB)

Handling Instructions (2659 KB)

References

[1]. Chen HQ, et al. 4'-O-methylbavachalcone alleviates ischemic stroke injury by inhibiting parthanatos and promoting SIRT3. Eur J Pharmacol. 2024;972:176557. [Content Brief]

[2]. Kim DW, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem. 2014;29(1):59-63. [Content Brief]

[3]. Sun H, et al. 4'‑O‑methylbavachalcone inhibits succinate induced cardiomyocyte hypertrophy via the NFATc4 pathway. Exp Ther Med. 2023;25(4):172. Published 2023 Mar 6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.9551 mL	14.7754 mL	29.5508 mL	73.8771 mL
	5 mM	0.5910 mL	2.9551 mL	5.9102 mL	14.7754 mL
	10 mM	0.2955 mL	1.4775 mL	2.9551 mL	7.3877 mL
	15 mM	0.1970 mL	0.9850 mL	1.9701 mL	4.9251 mL
	20 mM	0.1478 mL	0.7388 mL	1.4775 mL	3.6939 mL
	25 mM	0.1182 mL	0.5910 mL	1.1820 mL	2.9551 mL
	30 mM	0.0985 mL	0.4925 mL	0.9850 mL	2.4626 mL
	40 mM	0.0739 mL	0.3694 mL	0.7388 mL	1.8469 mL
	50 mM	0.0591 mL	0.2955 mL	0.5910 mL	1.4775 mL
	60 mM	0.0493 mL	0.2463 mL	0.4925 mL	1.2313 mL
	80 mM	0.0369 mL	0.1847 mL	0.3694 mL	0.9235 mL
	100 mM	0.0296 mL	0.1478 mL	0.2955 mL	0.7388 mL